Erratum (DOI:10.1016/j.arcmed.2007.05.003);Interaction between iNOS and COX-2 in Hypoxia-Induced Retinal Neovascularization in Mice

Archives of Medical Research

Volumn 38, Issue 8, 2007, Pages 807-815

  He, Tao ^a   Xing, Yi Qiao ^a   Zhao, Xiao Hui ^a   Ai, Ming ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

COX 2; iNOS; MMP 2; Retinal neovascularization

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GELATINASE A; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; HYPOXIA; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; RETINA NEOVASCULARIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING;

EID: 34848827970     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2007.11.005     Document Type: Erratum

References (25)

1. Werdich X.Q., McCollum G.W., Rajaratnam V.S., and Penn J.S. Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy. Exp Eye Res 79 (2004) 623-630
2. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., et al. Cyclooxygenase in biology and disease. FASEB J 12 (1998) 1063-1073
3. Wilkinson-Berka J.L., Alousis N.S., Kelly D.J., and Gilbert R.E. COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 44 (2003) 974-979
4. Toda N., and Nakanishi-Toda M. Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy. Prog Retin Eye Res 26 (May 2007) 205-238
5. Nathan C., and Xie Q.W. Nitric oxide synthase: roles, tolls, and controls. Cell 78 (1994) 915-918
6. Sennlaub F., Courtois Y., and Goureau O. Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J Clin Invest 107 (2001) 717-725
7. Du Y., Sarthy V.P., and Kern T.S. Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am J Physiol Regul Integr Comp Physiol 287 (2004) 735-741
8. Notoya K., Jovanovic D.V., Reboul P., Martel-Pelletier J., Mineau F., and Pelletier J.P. The induction of cell death in human osteoarthritis chondrocytes by nitric oxide is related to the production of prostaglandin E2 via the induction of cyclooxygenase-2. J Immunol 165 (2000) 3402-3410
9. Matrisian L.M. Metalloproteinases and their inhibitors in matrix remodeling. Trend Genet 6 (1990) 121-125
10. Plantner J.J., Jiang C., and Smine A. Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration. Exp Eye Res 67 (1998) 637-645
11. Fini M.E., Cook J.R., and Mohan R. Proteolytic mechanisms in corneal ulceration and repair. Arch Dermatol Res 290 (1998) S12-S23
12. Kvanta A., Sarman S., Fagerholm P., Seregard S., and Steen B. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 70 (2000) 419-428
13. O'Brien T.P., Li Q.J., Sauerburger F., Reviglio V.E., Rana T., and Ashraf M.F. The role of matrix metalloproteinases in ulcerative keratolysis associated with perioperative diclofenac use. Ophthalmology 108 (2001) 656-659
14. Yang Y.N., Bauer D., Wasmuth S., Steuhl K.P., and Heiligenhaus A. Matrix metalloproteinases (MMP-2 and 9) and tissue inhibitors of matrix metalloproteinases (TIMP-1 and 2) during the course of experimental necrotizing herpetic keratitis. Exp Eye Res 77 (2003) 227-237
15. Majka S., McGuire P., Colombo S., and Das A. The balance between proteinases and inhibitors in a murine model of proliferative retinopathy. Invest Ophthalmol Vis Sci 42 (2001) 210-215
16. Maquoi E., Sounni N.E., Devy L., Olivier F., Frankenne F., Krell H.W., et al. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res 10 (2004) 4038-4047
17. Smith L.E., Wesolowski E., McLellan A., Kostyk S.K., D'Amato R., Sullivan R., et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35 (1994) 101-111
18. Cianchi F., Cortesini C., Fantappie O., Messerini L., Sardi I., Lasagna N., et al. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res 10 (2004) 2694-2704
19. Gaillard T., Mulsch A., Klein H., and Decker K. Regulation by prostaglandin E2 of cytokine-elicited nitric oxide synthesis in rat liver macrophages. Biol Chem Hoppe Seyler 373 (1992) 897-902
20. Marotta P., Sautebin L., and Di Rosa M. Modulation of the induction of nitric oxide synthase by eicosanoids in the murine macrophage cell line J774. Br J Pharmacol 107 (1992) 640-641
21. Poligone B., and Baldwin A.S. Positive and negative regulation of NF-B by COX-2: roles of different prostaglandins. J Biol Chem 276 (2001) 38658-38664
22. John A., and Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7 (2001) 14-23
23. Barnett J.M., McCollum G.W., Fowler J.A., Duan J.J., Kay J.D., Liu R.Q., et al. Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR. Invest Ophthalmol Vis Sci 48 (2007) 907-915
24. Sanchez M.C., Barcelona P.F., Luna J.D., Ortiz S.G., Juarez P.C., Riera C.M., et al. Low-density lipoprotein receptor-related protein-1 (LRP-1) expression in a rat model of oxygen-induced retinal neovascularization. Exp Eye Res 83 (2006) 1378-1385
25. Noda K., Ishida S., Shinoda H., Koto T., Aoki T., Tsubota K., et al. Hypoxia induces the expression of membrane-type 1 matrix metalloproteinase in retinal glial cells. Invest Ophthalmol Vis Sci 46 (2005) 3817-3824